Zenas BioPharma, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Zenas BioPharma, Inc. (ZBIO) reported Increase (Decrease) in Prepaid Expense and Other Assets of $5.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- Zenas BioPharma, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$1.11M.
- Zenas BioPharma, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $6.48M, a 1736.26% increase year-over-year.
- Zenas BioPharma, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $2.36M, a 71.17% decline year-over-year.
- Zenas BioPharma, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $1.60M.
- Zenas BioPharma, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $3.16M, a 59.02% decline from fiscal 2024.
- Zenas BioPharma, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $7.70M, a 129.95% increase from fiscal 2023.
- Zenas BioPharma, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $3.35M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $5.37M 10-Q · filed 2026-08-13 | $7.73M derived: sum of 3 quarters · filed 2026-08-13 | $9.33M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $6.48M 10-Q · filed 2026-05-13 | $8.84M derived: sum of 2 quarters · filed 2026-05-13 | $10.44M derived: sum of 3 quarters · filed 2026-05-13 | $9.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $3.96M derived: sum of 2 quarters · filed 2026-03-16 | $2.80M derived: sum of 3 quarters · filed 2026-08-13 | $3.16M 10-K · filed 2026-03-16 |
| 2025-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $446.00K derived: sum of 2 quarters · filed 2026-08-13 | $799.00K 10-Q · filed 2025-11-12 | $8.97M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$802.00K 10-Q · filed 2026-08-13 | $7.37M derived: sum of 3 quarters · filed 2026-08-13 | $5.58M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $353.00K 10-Q · filed 2026-05-13 | $8.53M derived: sum of 2 quarters · filed 2026-05-13 | $6.74M derived: sum of 3 quarters · filed 2026-05-13 | $9.84M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $8.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $6.39M derived: sum of 2 quarters · filed 2026-03-16 | $9.49M derived: sum of 3 quarters · filed 2026-03-16 | $7.70M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.31M derived: sum of 2 quarters · filed 2025-11-12 | -$475.00K 10-Q · filed 2025-11-12 | -$1.84M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.31M 10-Q · filed 2025-08-12 | -$50.00K derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$1.79M 10-Q · filed 2025-05-15 | -$3.15M derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $3.35M 10-K · filed 2025-03-11 | ||
| 2023-09-30 | $4.71M 10-Q · filed 2024-11-12 |